Lv4
650 积分 2024-07-23 加入
OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
3天前
已完结
Advances in the treatment of systemic lupus erythematosus
16天前
已完结
CAR T-cell Therapy in SLE: A Systematic Review
19天前
已完结
Safety and Efficacy of ianalumab in patients with Sjögren's disease:52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study
19天前
已完结
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
24天前
已完结
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
27天前
已完结
Simplified criteria for the diagnosis of autoimmune hepatitis
1个月前
已完结
Geoepidemiology of autoimmune liver diseases
1个月前
已关闭
Iscalimab in Adolescents and Young Adults with New-Onset Type 1 Diabetes
1个月前
已关闭
Type 1 Diabetes Mellitus
1个月前
已完结
皖公网安备34019202002308
